(Q37622551)

21 August 2017

1 reference

title

Anti-angiogenesis agents in metastatic or recurrent cervical cancer (English)

1 reference

21 August 2017

1 reference

cervix uterine cancer

1 reference

1

Bradley J Monk

1 reference

21 August 2017

Lyndsay J Willmott

2

1 reference

21 August 2017

Daniele A Sumner

series ordinal

3

1 reference

21 August 2017

language of work or name

English

0 references

publication date

27 October 2009

1 reference

21 August 2017

1 reference

21 August 2017

volume

116

1 reference

21 August 2017

issue

2

1 reference

21 August 2017

page(s)

181-186

1 reference

Global cancer statistics, 2002

21 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.09.033

7 January 2021

Cancer statistics, 2009

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.09.033

The evolution of cost-effective screening and prevention of cervical carcinoma: implications of the 2006 consensus guidelines and human papillomavirus vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.09.033

Multimodality therapy for locally advanced cervical carcinoma: state of the art and future directions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.09.033

Randomized phase III trial of cisplatin with or without topotecan in carcinoma of the uterine cervix: a Gynecologic Oncology Group Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.09.033

Cervical cancer therapy: current, future and anti-angiogensis targeted treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.09.033

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.09.033

HIFs and tumors--causes and consequences

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.09.033

Reversing hypoxic cell chemoresistance in vitro using genetic and small molecule approaches targeting hypoxia inducible factor-1.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.09.033

Angiogenesis in gynecological oncology-mechanism of tumor progression and therapeutic targets

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.09.033

Hypoxia-specific stabilization of HIF-1alpha by human papillomaviruses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.09.033

Markers of angiogenesis in high-risk, early-stage cervical cancer: A Gynecologic Oncology Group study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.09.033

Prognostic relevance of carbonic anhydrase-IX in high-risk, early-stage cervical cancer: a Gynecologic Oncology Group study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.09.033

Circulating serum levels of cytokines and angiogenic factors in patients with cervical cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.09.033

Serum vascular endothelial growth factor and serum leptin in patients with cervical cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.09.033

Vascular permeability factor (vascular endothelial growth factor) expression and angiogenesis in cervical neoplasia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.09.033

Gynecologic oncology group trials of chemotherapy for metastatic and recurrent cervical cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.09.033

When is being in a hurry going too fast? Lessons learned from clinical trials in cervical cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.09.033

Phase II trial of bevacizumab in the treatment of persistent or recurrent squamous cell carcinoma of the cervix: a gynecologic oncology group study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.09.033

Targeting angiogenesis: progress with anti-VEGF treatment with large molecules

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.09.033

Update on novel therapeutic agents for cervical cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.09.033

Overexpression of epidermal growth factor type-1 receptor (EGF-R1) in cervical cancer: implications for Cetuximab-mediated therapy in recurrent/metastatic disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.09.033

A phase II trial of erlotinib in recurrent squamous cell carcinoma of the cervix: a Gynecologic Oncology Group Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.09.033

10.1016/J.YGYNO.2009.09.033

7 January 2021

Identifiers

DOI

1 reference

release_cpc5zzaot5hdfpb7xaw33q4irq

21 August 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/cpc5zzaot5hdfpb7xaw33q4irq

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference